{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:48Z","timestamp":1788026328185,"version":"build-2784847793"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:p>Atopic dermatitis (AD) and prurigo nodularis (PN) are chronic inflammatory skin diseases that are characterized by intense pruritus. Nemolizumab is the first interleukin-31 blocking agent approved in the EU for the treatment of moderate-to-severe AD and PN. This article summarizes the key benefits and risks associated with nemolizumab and provides perspectives on the additional value of nemolizumab in the treatment armamentarium.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf259","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T09:35:53Z","timestamp":1751103353000},"page":"996-998","source":"Crossref","is-referenced-by-count":1,"title":["The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis"],"prefix":"10.1093","volume":"193","author":[{"given":"Hendy","family":"Kristyanto","sequence":"first","affiliation":[{"name":"European Medicines Agency , Domenico Scarlattilaan 6, 1083HS Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagrario","family":"Rey Torre","sequence":"additional","affiliation":[{"name":"European Medicines Agency , Domenico Scarlattilaan 6, 1083HS Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cunney","sequence":"additional","affiliation":[{"name":"European Medicines Agency , Domenico Scarlattilaan 6, 1083HS Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Dunder","sequence":"additional","affiliation":[{"name":"Swedish Medical Products Agency , Dag Hammarskjolds Vag 42, Uppsala Science Park, 752 37 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Bego","sequence":"additional","affiliation":[{"name":"Agency for Medicinal Products and Medical Devices of Croatia , Ksaverska Cesta 4, 10000 Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sepodes","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia da Universidade de Lisboa , Avenida Professor Gama Pinto 1649-003 Lisboa ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Castelnovo","sequence":"additional","affiliation":[{"name":"European Medicines Agency , Domenico Scarlattilaan 6, 1083HS Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"key":"2025101708271636700_ljaf259-B1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ijd.17707","article-title":"Type 2 inflammation and its role in dermatologic diseases","volume":"64","author":"Chovatiya","year":"2025","journal-title":"Int J Dermatol"},{"key":"2025101708271636700_ljaf259-B2","doi-asserted-by":"crossref","first-page":"639097","DOI":"10.3389\/fmed.2021.639097","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025101708271636700_ljaf259-B3","volume-title":"Nemluvio","author":"European Medicines Agency"},{"key":"2025101708271636700_ljaf259-B4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"2025101708271636700_ljaf259-B5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"OLYMPIA 1 Investigators. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2025101708271636700_ljaf259-B6","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"2025101708271636700_ljaf259-B7","doi-asserted-by":"crossref","first-page":"e15115","DOI":"10.1111\/exd.15115","article-title":"IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice","volume":"33","author":"Kawai","year":"2024","journal-title":"Exp Dermatol"},{"key":"2025101708271636700_ljaf259-B8","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljaf166","article-title":"Living network meta-\u00adanalysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis","volume":"193","author":"Drucker","year":"2025","journal-title":"Br J Dermatol"},{"key":"2025101708271636700_ljaf259-B9","doi-asserted-by":"crossref","first-page":"adv43419","DOI":"10.2340\/actadv.v105.43419","article-title":"Four cases of prurigo nodularis requiring nemolizumab due to persistent pruritus or lesions after dupilumab treatment","volume":"105","author":"Mima","year":"2025","journal-title":"Acta Derm Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf259\/63615902\/ljaf259.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/5\/996\/63615902\/ljaf259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/5\/996\/63615902\/ljaf259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:27:26Z","timestamp":1760704046000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/5\/996\/8177135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6,28]]},"published-print":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf259","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,28]]}}}